Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Triptorelin in the Treatment of Prostate Cancer

Triptorelin in the Treatment of Prostate Cancer Triptorelin is a synthetic analog of gonadotropin-releasing hormone (GnRH; also known as luteinizing hormone-releasing hormone [LHRH]), which has enhanced receptor affinity, extended half-life and increased bioactivity. Triptorelin initially stimulates the pituitary gland, increasing serum luteinizing hormone and testosterone levels; however, after 3–4 weeks, the pituitary becomes refractory due to receptor desensitization and/or down-regulation, resulting in castration levels of testosterone in men and postmenopausal estradiol levels in women. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png American Journal of Cancer Springer Journals

Triptorelin in the Treatment of Prostate Cancer

American Journal of Cancer , Volume 4 (3) – Aug 10, 2012

Loading next page...
 
/lp/springer-journals/triptorelin-in-the-treatment-of-prostate-cancer-80dZJI5ATW
Publisher
Springer Journals
Copyright
Copyright © 2005 by Adis Data Information BV
Subject
Pharmacy; Pharmacy
ISSN
1175-6357
DOI
10.2165/00024669-200504030-00004
Publisher site
See Article on Publisher Site

Abstract

Triptorelin is a synthetic analog of gonadotropin-releasing hormone (GnRH; also known as luteinizing hormone-releasing hormone [LHRH]), which has enhanced receptor affinity, extended half-life and increased bioactivity. Triptorelin initially stimulates the pituitary gland, increasing serum luteinizing hormone and testosterone levels; however, after 3–4 weeks, the pituitary becomes refractory due to receptor desensitization and/or down-regulation, resulting in castration levels of testosterone in men and postmenopausal estradiol levels in women.

Journal

American Journal of CancerSpringer Journals

Published: Aug 10, 2012

References